GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 62,850 shares, a decrease of 76.9% from the June 15th total of 271,752 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average daily volume of 436,362 shares, the short-interest ratio is currently 0.1 days.

GeoVax Labs Stock Performance

GeoVax Labs stock opened at $1.11 on Tuesday. The stock has a market capitalization of $3.85 million, a price-to-earnings ratio of -0.06 and a beta of 3.68. GeoVax Labs has a 52-week low of $0.96 and a 52-week high of $23.10. The stock’s 50 day moving average price is $1.65 and its two-hundred day moving average price is $2.08.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter. On average, equities research analysts forecast that GeoVax Labs will post -8.69 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GOVX shares. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Tuesday, April 21st. Finally, D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $150.00.

Institutional Trading of GeoVax Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in GeoVax Labs in the first quarter valued at approximately $27,000. HRT Financial LP acquired a new stake in GeoVax Labs in the 4th quarter valued at $31,000. Hudson Bay Capital Management LP acquired a new stake in GeoVax Labs in the 3rd quarter valued at $47,000. Renaissance Technologies LLC bought a new stake in GeoVax Labs during the 4th quarter valued at $104,000. Finally, Armistice Capital LLC bought a new stake in GeoVax Labs during the 3rd quarter valued at $253,000. 6.09% of the stock is owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.